Trillium Therapeutics Inc (TRIL) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Trillium Therapeutics Inc.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
TRIL Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for TRIL as an investment opportunity.
- The percent of analysts bearish on the stock of TRIL is less than nearly 100% of all US stocks.
- Trillium Therapeutics Inc's number of analysts covering the stock is higher than 95.9% of stocks in the micro market cap category.
- Trillium Therapeutics Inc's variance in analysts' estimates is lower than 11.45% of stocks in the micro market cap category.
- Trillium Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 13.16% of Pharmaceutical Products stocks.
- Trillium Therapeutics Inc's percentage of analysts bullish on the stock is higher than 82.06% of all US stocks.
- TRIL has a greater average analyst price target than 79.7% of stocks in the micro market cap category.
- TRIL has a lower change in bullishness amongst analysts than nearly 100% of all US stocks.
What is the outlook for TRIL? Use POWR Ratings for clearer insight into price direction.